Home>Topics>Companies>Sanofi S.A.

Sanofi S.A.

  1. All
  2. Commentary
  3. Stock Reports
  4. Video Reports
  5. Fund Reports
  6. ETF Reports
  7. Headlines
  1. Ilumina collaborates with members of Big Pharma on molecular diagnostics

    Headlines

    Thu, 21 Aug 2014

    ILMN ) has formed collaborative partnerships with AstraZeneca (NYSE: AZN ), Janssen Biotech (NYSE: JNJ ) and Sanofi (NYSE: SNY ) to develop a universal next-generation sequencing (NGS) system focused on oncology. The system will employ

  2. U.S. FDA approves Sanofi's Gaucher disease drug Cerdelga

    Headlines

    Tue, 19 Aug 2014

    Aug 19 (Reuters) - The U.S. Food and Drug Administration said on Tuesday it has approved Sanofi SA 's drug Cerdelga to treat patients with type 1 Gaucher disease, a rare genetic disorder.

  3. Second Quarter Results Confirm Why We Like Aastrom

    Headlines

    Tue, 19 Aug 2014

    of operations for the company's recently acquired Cell Therapy and Regenerative Medicine (CTRM) business from Sanofi (NYSE: SNY ), previously known as Genzyme Biosurgery Aps. Total revenues for the quarter were approximately $4.4 million

  4. Lilly gets tentative approval for diabetes drug

    Headlines

    Tue, 19 Aug 2014

    Basaglar meets all the criteria for market clearance, it is tentative because of the automatic 30-month stay due to Sanofi 's ( SNY -0.8% ) patent infringement suit . The agency cannot issue final approval until the stay ends (mid-2016) or

  5. Sanofi Bolsters Vaccine Business

    Headlines

    Mon, 18 Aug 2014

    By Alan Kotok : Sanofi Pasteur, the vaccines ..... pharmaceutical company Sanofi (NYSE: SNY ), reported last week ..... improving performance of Sanofi 's vaccine division, known as Sanofi Pasteur, the weakest division

  6. Week In Review: ZAI Lab In-Licenses 2 Sanofi Drug Candidates

    Headlines

    Sun, 17 Aug 2014

    of stealth mode by announcing a major deal: the company has obtained global rights for two novel compounds from Sanofi (NYSE: SNY ), both of which are potential treatments for chronic respiratory diseases. ZAI is led by Dr. Samantha Du, who

  7. 10 Known Unknowns That Matter For MannKind Investors

    Headlines

    Thu, 14 Aug 2014

    Pundits of all stripes are opining about the Mannkind- Sanofi partnership without knowing any of the facts. Many statements ..... diabetes drugs are sold. I have already explained why Sanofi (NYSE: SNY ) was by far the best partner that Mannkind (NASDAQ

  8. Properly Treating Costs: Re-Evaluating The MannKind And Sanofi Partnership

    Headlines

    Wed, 13 Aug 2014

    Eiseman : The partnership between Sanofi (NYSE: SNY ) and MannKind (NASDAQ: MNKD ..... one commenter has suggested, that Sanofi is paying MannKind for its prior ..... well over $1 billion in Afrezza. Sanofi , in addition to making upfront and

  9. InterMune up on takeout rumors

    Headlines

    Wed, 13 Aug 2014

    InterMune ( ITMN +14.3% ) spike on a 2x surge in volume in response to rumors that Roche ( OTCQX:RHHBY +0.4% ), Sanofi ( SNY +0.7% ), Glaxo ( GSK -0.1% ) and Actelion ( OTCPK:ALIOF ) ( OTC:ACIOY ) are preparing offers. Trading in

  10. Update: MannKind Q2 Earnings - Stock Sent To The Woodshed

    Headlines

    Wed, 13 Aug 2014

    announcement of a lucrative licensing agreement with Sanofi (NYSE: SNY ) for the commercialization of Afrezza. I expected this ..... disclose important details about its partnership with Sanofi due to competitive reasons, which clearly didn't sit

« Prev12345Next »
Content Partners